Therapeutic Advances in Urology (Jan 2019)

Role of NLRP3 inflammasome in the development of bladder pain syndrome interstitial cystitis

  • Karol Borys Tudrej,
  • Tomasz Piecha,
  • Małgorzata Kozłowska-Wojciechowska

DOI
https://doi.org/10.1177/1756287218818030
Journal volume & issue
Vol. 11

Abstract

Read online

Although it has been proposed that NOD-like receptor protein 3 (NLRP3) inflammasome activation may have an important contribution to the onset of bladder pain syndrome/interstitial cystitis (BPS/IC), as of today there is still insufficient evidence to accept or to reject this hypothesis. However, taking into consideration that inflammasomes have been already shown as important mediators of cyclophosphamide-induced bladder inflammation and that some studies have also revealed human bladder epithelium expresses high levels of NLRP3, such a hypothesis seems to be reasonable. The purpose of this review is to discuss a scenario that NLRP3 inflammasome is a crucial player in the development of this disease. Identification of a novel mediator of bladder inflammation and pain could lead to emerging new therapeutic strategy and the first causative therapy.